While good glycemic control has been shown to prevent microvascular complications (e.g. retinopathy, nephropathy, neuropathy), only a few anti-diabetic agents have been shown to reduce macrovascular complications (e.g. cardiovascular events. Empagliflozin, a sodium glucose transporter-2 (SGLT2) inhibitor, not only reduced the risk of CV events but also all-cause mortality in the EMPA-REG OUTCOME study. Based on this data, the SGLT2 inhibitors were given favorable second-line treatment status in the most recent AACE/ACE clinical practice guidelines. But do all SGLT2 inhibitors confer the same benefits… and risks? The Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial assessed the cardiovascular and renal benefits from long-term canagliflozin use. The results are both reassuring and unexpected.
Guest Author: Sean Lasota, Pharm.D.
Music by Good Talk
Is Home Blood Pressure Monitoring a “Home Run” for Blood Pressure Management?
Increasing the Patient-Clinician Connection: the “Presence 5 Practices”
FAST Take: Update on Febuxostat Cardiovascular Safety
Metformin During Pregnancy: Are the Results MiTy Enough to Change Practice?
Can a Polypill ‘TIP’ the Scale to a One-Size-Fits All Approach?
There’s an App for That! Can Smartphone Apps Assist with Smoking Cessation?
DECLARE-ing Another Victory for Dapagliflozin
Closing the Loop for Children with Type 1 Diabetes
Is it Time to Add Colchicine to the CVD Cocktail?
Canagliflozin Comeback? New Data on the Risk of Amputation
Using shared decision-making tools: Are they worth it?
Less Might Be Better: Deprescribing Antihypertensive Medications in Older Adults
Extracting Data on CBD: Effects on Opioid Use and Quality of Life
I Screen, You Screen, We Should All Screen for Unhealthy Drug Use
Implementing Comprehensive Medication Management – Ingredients for Success
Can VOYAGER Put PAD Patients Back on Their Feet?
Will Bempedoic Acid provide SERENITY for Patients with Statin Intolerance?
No Provider Status, No Problem: CCM as a Revenue Source in Community Pharmacy
Powerful Placebos and Notorious Nocebos: Implications for Ambulatory Care
An Incli-ng of Benefit? Efficacy and Safety of Inclisiran for Elevated LDL
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive